Diabetes Dx & Pathophys Flashcards
diabetes - defined
*a disease characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both
*various types of diabetes:
-type 1 = beta cell destruction; no insulin secretion
-type 2 = insulin resistance; defect in insulin action
-gestational = beta cell dysfunction and insulin resistance during pregnancy
-miscellaneous = drug induced, exocrine pancreatic disease, monogenic diabetes (MODY), LADA
diabetes - clinical presentation
- often asymptomatic
- the 3 P’s: polyuria, polydipsia, polyphagia
-excess glucose causes osmotic diuresis → polydipsia
-glucose cannot enter cells → low energy → polyphagia - weight loss (body is unable to utilize glucose as fuel; muscle & fat are broken down as alternatives)
- blurry vision, distal paresthesias
- diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS)
diabetes - diagnosis
- 8hr fasting plasma glucose 126+ mg/dL
- 2hr glucose tolerance test 200+ mg/dL (check fasting plasma glucose, drink 75g glucose drink, then recheck glucose 2hrs later)
- random plasma glucose 200+ AND hyperglycemia sx present
- HbA1c 6.5% or higher
*note - cannot rely on just one test: either repeat the same test or perform another to officially make the dx
hemoglobin A1c (HbA1c) - overview
*glucose attaches to Hb by nonenzymatic glycosylating in a high glucose environment (more glucose in blood → more glucose attaches to Hb)
*A1c represents the average glucose over a 3-month period (average lifespan on an RBC)
*assumes stable Hb (blood transfusions, hemoglobinopathies, etc can change HbA1c)
why do we treat diabetes?
*diabetes, when uncontrolled, can lead to multiple complications over time
*heart disease is the leading cause of death for pts with diabetes
type 1 diabetes - overview
*characterized by destruction of the pancreatic beta cells, resulting in absent insulin secretion
*most cases are diagnosed before age 18
type 1 diabetes (T1DM) - pathogenesis
*beta cell destruction is mediated by both T and B lymphocytes:
-T lymphocytes - infiltrate the islets and destroy the beta cells (insulitis)
-B lymphocytes - autoantibody-mediated destruction of beta islet cells
*antibodies also target glutamic acid decarboxylase (GAD), an enzyme that controls insulin release from the beta cells
*a type IV cell-mediated hypersensitivity reaction
type 1 diabetes (T1DM) - presentation
*often symptomatic at the time of dx as patients present with severe hyperglycemia
*polyuria, polydipsia, polyphagia
type 1 diabetes (T1DM) - diagnosis
*diagnose with previous screening tests (fasting glucose, glucose tolerance test, HbA1c, etc) AND:
-anti-glutamic acid decarboxylase antibodies (GAD)
-other antibodies: islet cell cytoplasmic antibodies, insulin antibodies, etc
type 1 diabetes (T1DM) - associations
*associated with mutations in HLA antigens: HLA-DR3 and HLA-DR4 but T1DM has a weaker genetic component than T2DM
*associated with other autoimmune conditions: hypothyroidism, vitiligo, celiac disease
type 1 diabetes (T1DM) - prognosis
*without insulin, T1DM is fatal
*now, good prognosis
type 2 diabetes (T2DM) - overview
*a “relative” insulin deficiency; a mismatch between insulin production and requirements driven by insulin resistance
*insulin resistance:
-a decrease in tissue responsiveness to insulin
-increased insulin levels required to maintain normal glucose
type 2 diabetes (T2DM) - pathophysiology
*cause of insulin resistance unclear but correlates with obesity, sedentary lifestyle, high triglycerides, inflammation, and cytokines
*beta cells compensate initially with excess insulin secretion, but continued hyperglycemia can impair beta cell function and they fail → T2DM; a vicious cycle
type 2 diabetes (T2DM) - epidemiology
*diagnosed in adulthood, usually > 40yo
*age of onset is shifting to younger adults/kids with obesity on the rise
type 2 diabetes (T2DM) - associations
*obesity increases the risk of metabolic syndrome: constellation of visceral or intra-abdominal adiposity, insulin resistance, hyperinsulinemia, glucose intolerance, HTN, HLD, and low HDL
*metabolic syndrome, in turn, increases the risk of T2DM and CVD